Eli Lilly (LLY) fell 2% premarket but holds at its 200-DMA. Analysts see upside ahead of Q1 earnings. Guggenheim targets $1,183 for 31% gain, while Morgan Stanley sees 47% upside to $1,327. Recent acquisitions like Kelonia boost confidence despite lower Foundayo uptake relative to Novo's Wegovy.